Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03603964 · ClinicalTrials.gov registry record · Phase 2
Guadecitabine Extension Study
A Phase 2 study, sponsored by Astex Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT03603964 is a Phase 2 study that was terminated before completion, run by Astex Pharmaceuticals. The registered enrollment target is 35 participants.
The verdict
NCT03603964, a Phase 2 study, was terminated before completion, sponsored by Astex Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a multicenter, open-label extension study for participants who participated in a previous Astex-sponsored guadecitabine clinical study \[including but not limited to SGI-110-01 (NCT01261312), SGI-110-04 (NCT02348489), SGI-110-06 (NCT02920008), and SGI-110-07 (NCT02907359)\].
Interventions
- DRUG Guadecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-07-18 |
| Est. Completion | 2021-10-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03603964
The ClinicalTrials.gov registry entry for NCT03603964 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Guadecitabine is the first listed.
NCT03603964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03603964 about?
NCT03603964 is a clinical study titled "Guadecitabine Extension Study". This is a multicenter, open-label extension study for participants who participated in a previous Astex-sponsored guadecitabine clinical study \[including but not limited to SGI-110-01 (NCT01261312), SGI-110-04 (NCT02348489), SGI-110-06 (NCT02920008), and SGI-110-07 (NCT02907359)\].
What is the current status of trial NCT03603964?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2018-07-18. Estimated completion is 2021-10-04.
What interventions are being tested in trial NCT03603964?
The interventions under investigation include: Guadecitabine (DRUG).
Who is sponsoring clinical trial NCT03603964?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.